Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial
Research output: Contribution to journal › Journal article › peer-review
OBJECTIVES: To elucidate the prognostic power of serum osteoprotegerin (OPG) in patients with stable coronary artery disease (CAD).
METHODS: Serum OPG levels were measured in the CLARICOR trial cohort of 4063 patients with stable CAD on blood samples drawn at randomization. The follow-up was 2.6 years for detailed cardiovascular events and 6 years for all-cause mortality.
RESULTS: OPG levels were significantly increased in non-survivors (21%) compared to survivors (median [quartiles] 2092 ng/L [1636; 2800] compared to 1695 ng/L [1322; 2193, p < 0.0001]). The 2.6-year follow-up showed that OPG adds to the prediction of both cardiovascular and all-cause mortality in combination with clinical risk factors (HR [one log10 unit increase] 6.1 [95% CI 2.4-15.6, p = 0.0001]) and HR 6.5 [95% CI 3.4-12.5, p < 0.0001], respectively). Similar, in the 6-year follow-up, OPG was found to be a strong predictor for all-cause mortality. Importantly, OPG remained an independent predictor of mortality even after adjustment for both clinical and conventional cardiovascular risk markers (HR 2.5 [95% CI 1.6-3.9, p < 0.0001]).
CONCLUSIONS: Serum OPG has a long-lasting independent predictive power as to all-cause mortality and cardiovascular death in patients with stable CAD.
Original language | English |
---|---|
Journal | Scandinavian Journal of Clinical & Laboratory Investigation |
Volume | 74 |
Issue number | 8 |
Pages (from-to) | 657-664 |
Number of pages | 8 |
ISSN | 0036-5513 |
DOIs | |
Publication status | Published - Nov 2014 |
ID: 135186856